Multiple Myeloma Clinical Trial
Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients
To demonstrate the benefit of treatment-a-promising-new-option-for-relapsed-multiple-myeloma/" >isatuximab in combination with carfilzomib and dexamethasone in the prolongation of Progression Free Survival (PFS) as compared to carfilzomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma (MM) previously treated with 1 to 3 lines of therapy.
To evaluate the Overall Response Rate (ORR), rate of very good partial response (VGPR) or better and complete response (CR) rate in both arms using International Myeloma Working Group (IMWG) criteria.
To evaluate rate of VGPR or better with minimal residual disease (MRD) negativity in both arms using IMWG criteria.
To evaluate the Overall Survival (OS) in both arms.
To evaluate safety in both arms.
To evaluate duration of response (DOR) in both arms.
To evaluate the Time To Progression (TTP) in both arms.
To evaluate the Second Progression Free Survival (PFS2) in both arms.
To evaluate the Time to first response
To evaluate the Time to best response
To determine the Pharmacokinetic profile of isatuximab in combination with carfilzomib.
To evaluate the immunogenicity of isatuximab in isatuximab arm.
To assess disease-specific and generic health-related quality of life (HRQL), disease and treatment-related symptoms, health state utility, and health status in both arms.
The duration of the study for the participants will include a period for screening of up to 3 weeks. Participants will continue study treatment until disease progression, unacceptable adverse reaction, participants' wish or other reason of discontinuation. During follow-up, participants who discontinue the study treatment due to progression of the disease will be followed every 3 months (12 weeks) for further anti-myeloma therapies, progression free survival to the second progression and survival, until death or the cut-off date, whichever comes first. Participants who discontinue the study treatment prior to documentation of disease progression will be followed-up every 4 weeks until confirmation of disease progression, and then every 3 months (12 weeks) for further anti-myeloma therapies, progression free survival to the second progression and survival, until death or the cut-off date, whichever comes first. After progression free survival analysis, participants will be followed yearly for 3 years for survival.
Participants with MM previously treated with prior 1 to 3 lines and with measurable serum M-protein (>= 0.5 gram/deciliter) and/or urine M-protein (>= 200 milligram/24 hours).
Participants previously pretreated with carfilzomib, who never achieved at least one minor response during previous therapies and/or last previous therapy completed within 14 last days.
Participants with serum free light chain (FLC) measurable disease only.
Participants less than 18 years old, participants with Eastern Cooperative Oncology Group performance status more than 2.
Participants with inadequate biological tests.
Participants with myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, New York Heart Association class III or IV congestive heart failure, superior or equal to grade 3 arrhythmias, stroke or transient ischemic attack within last 6 months, and/or left ventricular ejection fraction lower than 40%.
Participants with previous cancer unless disease free for more than 5 years or in situ cancer curatively treated.
Participants with known acquired immunodeficiency syndrome related illness or human immunodeficiency virus requiring antiretroviral treatment, or hepatitis A, B, or C active infection.
Women of childbearing potential or male participant with women of childbearing potential who do not agree to use highly effective method of birth control.
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 61 Locations for this study
San Francisco California, 94117, United States
Spartanburg South Carolina, 29303, United States
Blacktown , 2148, Australia
Fitzroy , 3065, Australia
Heidelberg West , 3081, Australia
Nedlands , 6009, Australia
Tweed Heads , 2485, Australia
West Perth , 6005, Australia
Wollongong , 2500, Australia
Barretos , 14784, Brazil
Porto Alegre , 90110, Brazil
Rio De Janeiro , 22793, Brazil
Salvador , 40110, Brazil
Sao Paulo , 05403, Brazil
Montreal , H1T 2, Canada
Saint John , E2L 4, Canada
Surrey , V3V 1, Canada
Brno , 62500, Czechia
Olomouc , 77900, Czechia
Ostrava - Poruba , 70852, Czechia
Praha 2 , 12808, Czechia
Lille , 59037, France
Nantes , 44093, France
Paris , 75012, France
Pessac , 33600, France
Pierre Benite Cedex , 69495, France
Poitiers Cedex , 86021, France
Athens , 10676, Greece
Athens , 11527, Greece
Athens , 11528, Greece
Patra , 26504, Greece
Thessaloniki , 57010, Greece
Budapest , 1083, Hungary
Budapest , 1097, Hungary
Budapest , 1125, Hungary
Kaposvár , 7400, Hungary
Bologna , 40138, Italy
Pisa , 56126, Italy
Reggio Emilia , 42123, Italy
Torino , 10126, Italy
Kumamoto-Shi , , Japan
Shibuya-Ku , , Japan
Shinjuku-Ku , , Japan
Shiwa-Gun , , Japan
Sunto-Gun , , Japan
Suwa-Shi , , Japan
Yamagata-Shi , , Japan
Busan , 49201, Korea, Republic of
Gangnam-Gu , 06351, Korea, Republic of
Seoul , 03080, Korea, Republic of
Seoul , 03722, Korea, Republic of
Seoul , 06591, Korea, Republic of
Auckland , 2025, New Zealand
Wellington , , New Zealand
Ekaterinburg , 62010, Russian Federation
Kirov , 61002, Russian Federation
Novosibirsk , 63004, Russian Federation
Badalona , 08916, Spain
Barcelona , 08036, Spain
Madrid , 28041, Spain
Sevilla , 41013, Spain
Valencia , 46017, Spain
Adana , 01250, Turkey
Ankara , 06500, Turkey
Bursa , 16059, Turkey
İstanbul , , Turkey
Samsun , 55139, Turkey
Bristol , BS2 8, United Kingdom
Leicester , LE1 5, United Kingdom
Plymouth , PL6 8, United Kingdom
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.